FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, today announced the initiation of the first study in older adults of M2SR, the company’s investigational supra-seasonal, live, single-replication, intranasal influenza (flu) vaccine. Funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), this study will assess the safety, tolerability, and immunological response to M2SR in adults up to age 85, a population most vulnerable to serious complications and mortality from the flu. The study will evaluate subjects’ ability to raise antibodies against matched and drifted strains of the influenza virus.
Read more at PRNewswire.